Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Core Insights - The FDA approved Emergent BioSolutions Inc.'s supplemental Biologics License Application for ACAM2000 to include prevention of mpox disease in high-risk individuals [1][3] - The approval is based on human safety data and a controlled animal study demonstrating the vaccine's effectiveness against mpox virus exposure [2] - Emergent plans to donate 50,000 doses of ACAM2000 for deployment in Central Africa as part of its support for the mpox outbreak response [4] Company Overview - Emergent BioSolutions is known for its ACAM2000 vaccine, which was first approved in 2007 for smallpox prevention in high-risk individuals [3] - The company has filed an Expression of Interest with the WHO for the ACAM2000 vaccine to be considered for Emergency Use Listing amid the mpox outbreak [3] Market Response - Following the FDA approval, Emergent BioSolutions' stock rose by 15.70% to $10.31 during the premarket session [5]